TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to ...

The randomized, double-blind, placebo controlled parallel group decentralized trial will enroll 60 patients with idiopathic Mast Cell Activation Syndrome (“MCAS”).

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome May 28, 2025 8:00 AM ET ...

Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab ...

Quantum BioPharma (NASDAQ: QNTM) continues to advance its pipeline targeting brain disorders and alcohol health, with Singular Research highlighting ...

Mast cells were shown to accumulate around the periphery of the invasive and metastatic rat mammary adenocarcinoma (MTLn3), and histological evidence of mast cell degranulation was observed during ...

Expert Rev Clin Immunol. 2012;8(3):235-241. Psychosocial stress can exacerbate the psoriatic skin disease in 40–80% of patients, but the mechanism is not clear. Factors induced during stress in ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...

PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND ...

Study Aims to Expedite Potentially Transformative Therapies By Assessing Safety and Efficacy of FSD202Melbourne, Australia, June 02, 2025 (GLOBE NEWSWIRE) -- iNGENū CRO, a leading full-service ...

The transcription factor GATA-binding protein 3 (GATA3) is best known as a master regulator of T-helper-2-cell differentiation. However, as part of a network of other transcription factors, GATA3 ...